A practical reference on PPARδ agonist: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-09. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Solubility | Soluble in dimethyl sulfoxide and some organic solvents; practically insoluble in water | Solvent choice affects laboratory handling |
| Typical storage | -20 °C, desiccated, protected from light | Common condition for research samples |
| Analytical method | Liquid chromatography–tandem mass spectrometry (LC-MS/MS) | Used for identification and quantification in biological or product samples |
| Common synonyms | GW501516, GW-501516, GSK-516, Endurobol | Names found in research and anti-doping literature |
| Regulatory status | Unapproved therapeutic; prohibited in competitive sport | Status can vary by country and context |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
While observing scouting photos of Cape Town, the filmmakers noticed a large three-walled external space that looked like an interior when filmed at night. A key sequence involving Ma-Ma and her gang firing rotary cannons across the atrium in their attempt to kill Judge Dredd required ten days of filming and eight different sets inside and outside the studio which were blended together with visual effects. Visual effects supervisor Jon Thum was unable to accompany a helicopter flight to obtain planned aerial shots of Johannesburg due to last-minute flight permissions; the resulting shots were non-specific and Thum had to pick out ones that could tell the story. Mantle had to develop new rigs to obtain close-up shots. Describing the aesthetic he aimed to achieve, he said: "I hope it will be more painterly. If we get it right, it will be a cross between Blade Runner and Clockwork Orange." Garland was a constant presence on the shoot; Urban turned to Garland for direction instead of Travis.
=== American Hospital Association (AHA) === The American Hospital Association has expressed concern that FDA's proposal to classify LDTs as medical devices exceeds the agency's appropriate regulatory scope, urging the FDA to continue to apply its enforcement discretion to hospital and health system LDTs and defer regulation of these tests mainly to CMS's strict CLIA oversight, the CAP accreditation and state law. The organization has called on Congress to either exclude hospitals and health systems from this device classification framework or to modernize LDT oversight in a way that promotes innovation while maintaining test accessibility, safety, and effectiveness.
== Career == At the institute, later Rockefeller University, he worked as an Assistant for Dr. D.W. Woolley on a dinucleotide growth factor he discovered in graduate school and on peptide growth factors that Woolley had discovered earlier. These studies led to the need for peptide synthesis and, eventually, to the idea for solid phase peptide synthesis (SPPS) in 1959. In 1963, he was sole author of a classic paper in the Journal of the American Chemical Society in which he reported a method he called "solid phase peptide synthesis". This article is the fifth most cited paper in the journal's history. In the mid-60s Dr. Merrifield's laboratory first synthesized bradykinin, angiotensin, desamino-oxytocin and insulin. In 1969, he and his colleague Bernd Gutte announced the first synthesis of the enzyme ribonuclease A. This work proved the chemical nature of enzymes. Dr. Merrifield's method greatly stimulated progress in biochemistry, pharmacology and medicine, making possible the systematic exploration of the structural basis of the activities of enzymes, hormones and antibodies. The development and applications of the technique continued to occupy his laboratory, where he remained active at the bench until recently. In 1993, Jeffrey I. Seeman published Life during a Golden Age of Peptide Chemistry, Merrifield's autobiography, in the series "Profiles, Pathways, and Dreams" for the American Chemical Society. He received the Association of Biomolecular Resource Facilities Award for outstanding contributions to Biomolecular Technologies in 1998.
=== Pain === Amitriptyline alleviates painful diabetic neuropathy. It is recommended by a variety of guidelines as a first or second-line treatment. It is as effective for this indication as gabapentin or pregabalin but less well tolerated. Amitriptyline is as effective at relieving pain as duloxetine. Combination treatment of amitriptyline and pregabalin offers additional pain relief for people whose pain is not adequately controlled with one medication and is usually safe. Amitriptyline in certain formulations may also induce the level of sciatic-nerve blockade needed for local anesthesia therein. Here, it has been demonstrated to be of superior potency to bupivacaine, a customary long-acting local anesthetic. Low doses of amitriptyline moderately improve sleep disturbances and reduce pain and fatigue associated with fibromyalgia. It is recommended for fibromyalgia accompanied by depression by Association of the Scientific Medical Societies in Germany and as a second-line option for fibromyalgia, with exercise being the first line option, by European League Against Rheumatism. Combinations of amitriptyline and fluoxetine or melatonin may reduce fibromyalgia pain better than either medication alone. There is some (low-quality) evidence that amitriptyline may reduce pain in cancer patients. It is recommended only as a second-line therapy for non-chemotherapy-induced neuropathic or mixed neuropathic pain if opioids did not provide the desired effect. Moderate evidence exists in favor of amitriptyline use for atypical facial pain.
Israel say the refusal was because they intended to spread hate speech against Israel. Elin Jones confirms she will stand down as Llywydd of the Senedd following the next election. 8 April – Downing Street declines calls to officially back a campaign to buy British goods in the wake of the introduction of US trade tariffs, arguing that the UK is "an open-trading nation" and the government is "not going to tell people where they buy their stuff". The European Court of Human Rights rules that businessman Sir Philip Green's human rights were not breached when he was named in the House of Lords in relation to misconduct allegations in 2018. He was named in Parliament under the rule of Parliamentary privilege, which allows Members of Parliament and peers to speak without the threat of legal repercussions. 9 April King Charles gives a speech to the Italian Parliament. He and Queen Camilla also have a private meeting with Pope Francis at Vatican City. Leader of the Fire Brigades Union Steve Wright calls on Labour MPs to reject benefit cuts. Councillor for Talbot and Branksome Woods on Bournemouth, Christchurch and Poole Council Karen Rampton resigns from the Conservative Party. The Welsh Government confirms that the Senedd will vote on whether the Terminally Ill Adults (End of Life) Bill should apply to Wales if it successfully passes through the Westminster parliament. 10 April – The Cabinet Office is to lose a third of its posts as part of government reforms to the civil service, with 2,100 of the 6,500 positions to be cut.
Sources: en.wikipedia.org
=== Preventing further liver damage === Regardless of the underlying cause of cirrhosis, consumption of alcohol and other potentially damaging substances is discouraged. There is no evidence that supports the avoidance or dose reduction of paracetamol in people with compensated cirrhosis; it is thus considered a safe analgesic for said individuals. Vaccination against hepatitis A and hepatitis B is recommended early in the course of illness due to a decline in effectiveness of the vaccines with decompensation. Treating the cause of cirrhosis prevents further damage; for example, giving oral antivirals such as entecavir and tenofovir where cirrhosis is due to hepatitis B prevents progression of cirrhosis. Similarly, control of weight and diabetes prevents deterioration in cirrhosis due to non-alcoholic fatty liver disease. People with cirrhosis or liver damage are often advised to avoid drugs that could further harm the liver. These include several drugs such as anti-depressants, certain antibiotics, and NSAIDs (like ibuprofen). These agents are hepatotoxic as they are metabolized by the liver. If a medication that harms the liver is still recommended by a doctor, the dosage can be adjusted to aim for minimal stress on the liver.
== Stability == Avobenzone is sensitive to the properties of the solvent, being relatively stable in polar protic solvents and unstable in nonpolar environments. Also, when it is irradiated with UVA light, it generates a triplet excited state in the keto form which can either cause the avobenzone to degrade or it can transfer energy to biological targets and cause deleterious effects. Avobenzone has been shown to degrade significantly in light, resulting in less protection over time. The UV-A light in a day of sunlight in a temperate climate is sufficient to break down most of the compound. Data presented to the Food and Drug Administration by the Cosmetic, Toiletry and Fragrance Association indicates a −36% change in avobenzone's UV absorbance following one hour of exposure to sunlight. For this reason, in sunscreen products, avobenzone is always formulated together with a photostabilizer, such as octocrylene. Other photostabilizers include:
This distinction is particularly relevant in structural biology, materials science, and computational chemistry, where hydrogen bonding spans a continuum from weak van der Waals-like interactions to nearly covalent bonding. Hydrogen bonding can occur between separate molecules (intermolecular) or within different parts of the same molecule (intramolecular). Its strength varies considerably, depending on geometry, environment, and the donor-acceptor pair, typically ranging from 4.2 to 167.4 kJ/mol (1 to 40 kcal/mol). This places hydrogen bonds stronger than van der Waals interactions but generally weaker than covalent or ionic bonds. Hydrogen bonding plays a fundamental role in chemistry, biology, and materials science. It is responsible for the anomalously high boiling point of water, the stabilization of protein and nucleic acid structures, and key properties of materials like paper, wool, and hydrogels. In biological systems, hydrogen bonds mediate molecular recognition, enzyme catalysis, and DNA replication, while in materials science, they contribute to self-assembly, adhesion, and supramolecular organization.
Other effects have been reported to include confusion, lethargy, laziness, sleepiness, lightheadedness, feeling faintish and actual fainting, brief but repeated periods of amnesia, fear of psychosis, pupil dilation, paresthesia, nausea, vomiting, abdominal cramps, diarrhea, and muscle tremors, among others. The drug was described as a "seminal" or "archetypal" psychedelic in PiHKAL.
In most states, the IV injection is a series of drugs given in a set sequence, designed to first induce unconsciousness followed by death through paralysis of respiratory muscles and by cardiac arrest through depolarization of cardiac muscle cells. The execution of the condemned in most states involves three separate injections (in sequential order):
Sources: en.wikipedia.org
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.
No. It is not an anabolic-androgenic steroid; it is a synthetic PPARδ agonist. Because it is banned in sport, it is sometimes grouped with doping agents even though its chemical class differs from steroids.
Human data are limited and development was discontinued, so major effects and long-term risks are not well characterized. Some early studies examined metabolic markers, but they do not provide a basis for unsupervised use.
Cardarine is an investigational synthetic compound that acts as a PPARδ agonist. It is also known as GW501516 and has been studied mainly in preclinical research. It is not an approved medicine.